NWBOOTC

NORTHWEST BIOTHERAPEUTICS INC

Healthcare·Oncology·Commercial·Bethesda, MD, United States
OncologyOphthalmology

NORTHWEST BIOTHERAPEUTICS INC (NWBO): 3 pipeline candidates · 1 upcoming catalyst · ~1 mo cash runway. Updated within the last hour.

5.5/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway0.2

0.7 months

Financial Health10.0

D/E -2.34 · 0% dilution

Pipeline Maturity9.5

Lead: BLA Filed

Pipeline Breadth5.9

3 candidates

Catalyst Momentum2.0

1 upcoming, next in ~1554d

Insider SignalN/A

N/A

A transparent, data-derived signal for NORTHWEST BIOTHERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$310.6M

Cash

$1.8M

Quarterly Burn

$12.5M

Runway

0.7 mo

Revenue

$494K

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~Jul 2026
Today~56 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (3 candidates)

DrugPhase
dcvax-directPhase 1
dcvax-lBLA Filed
elamipretidePhase 3

Upcoming Catalysts (1)

Patent_ExpiryPatent/Exclusivity Expiry: FORZINITY

Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

3

Total value held

$58K

HolderSharesValue
kelleher financial advisors200,000$41K
vsm wealth advisory, llc80,574$17K
hantz financial services, inc.250$0
·CEO: Ms. Linda F. Powers J.D.

Frequently asked questions

How many drug candidates are in NORTHWEST BIOTHERAPEUTICS INC's pipeline?

NORTHWEST BIOTHERAPEUTICS INC (NWBO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NORTHWEST BIOTHERAPEUTICS INC's lead drug candidate?

NORTHWEST BIOTHERAPEUTICS INC's most advanced tracked candidate is dcvax-direct (Phase 1) for Inoperable solid tumors.

What is NORTHWEST BIOTHERAPEUTICS INC's next catalyst?

NORTHWEST BIOTHERAPEUTICS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FORZINITY" — expected September 19, 2030.

What is NORTHWEST BIOTHERAPEUTICS INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, NORTHWEST BIOTHERAPEUTICS INC has approximately 0.7 months of cash runway.

What is NORTHWEST BIOTHERAPEUTICS INC's market capitalization?

NORTHWEST BIOTHERAPEUTICS INC's market capitalization is approximately $310.6M.

Get the full picture on NORTHWEST BIOTHERAPEUTICS INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar